TY - JOUR
T1 - Effect of ebastine on serum eosinophil cationic protein levels in patients with bronchial asthma
AU - Horiguchi, Takahiko
AU - Tachikawa, Soichi
AU - Kasahara, Junichi
AU - Shiga, Mamoru
AU - Kondo, Rieko
AU - Miyazaki, Junichi
AU - Sugiyama, Masahiro
AU - Sasaki, Yasushi
AU - Hirose, Masahiro
N1 - Funding Information:
This study was supported by Dainippon Pharmaceutical Co. Ltd, Osaka, Japan.
PY - 1999
Y1 - 1999
N2 - Objective: This study evaluated the effects of ebastine on serum eosinophil cationic protein (ECP) levels in patients with bronchial asthma. Patients: Twenty patients with bronchial asthma (11 patients with atopic disease and nine with non-atopic disease) were enrolled in the study. Methods: In an open-label design, all patients received ebastine 10 mg/day for 4 weeks and serum ECP levels, peripheral blood eosinophil counts, morning peak expiratory flow rate (PEFR) and thresholds for airway hyper-responsiveness (D(min) in asthgraphy) were determined before and after treatment. Results: Serum ECP levels and peripheral blood eosinophil counts were significantly decreased. By disease type, no significant change was found in the non atopic patients, while the serum ECP level was significantly (p < 0.001) decreased in the atopic patients. Furthermore, no significant change in D(min) was found but PEFR was significantly (p < 0.019) increased in the atopic type. Conclusion: Ebastine not only inhibits type I allergic reactions, but may also inhibit airway inflammation by reducing serum ECP levels, particularly in patients with atopic bronchial asthma.
AB - Objective: This study evaluated the effects of ebastine on serum eosinophil cationic protein (ECP) levels in patients with bronchial asthma. Patients: Twenty patients with bronchial asthma (11 patients with atopic disease and nine with non-atopic disease) were enrolled in the study. Methods: In an open-label design, all patients received ebastine 10 mg/day for 4 weeks and serum ECP levels, peripheral blood eosinophil counts, morning peak expiratory flow rate (PEFR) and thresholds for airway hyper-responsiveness (D(min) in asthgraphy) were determined before and after treatment. Results: Serum ECP levels and peripheral blood eosinophil counts were significantly decreased. By disease type, no significant change was found in the non atopic patients, while the serum ECP level was significantly (p < 0.001) decreased in the atopic patients. Furthermore, no significant change in D(min) was found but PEFR was significantly (p < 0.019) increased in the atopic type. Conclusion: Ebastine not only inhibits type I allergic reactions, but may also inhibit airway inflammation by reducing serum ECP levels, particularly in patients with atopic bronchial asthma.
UR - http://www.scopus.com/inward/record.url?scp=0033024492&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033024492&partnerID=8YFLogxK
U2 - 10.2165/00044011-199917060-00003
DO - 10.2165/00044011-199917060-00003
M3 - Article
AN - SCOPUS:0033024492
SN - 1173-2563
VL - 17
SP - 435
EP - 440
JO - Clinical Drug Investigation
JF - Clinical Drug Investigation
IS - 6
ER -